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Background: DNAX accessory molecule-1 (DNAM-1) is an activating receptor constitutively expressed by macrophages/
dendritic cells and by T lymphocytes and Natural Killer (NK) cells, having an important role in anticancer responses; in
this regard, combination therapies able to enhance the expression of DNAM-1 ligands on tumor cells are of therapeutic
interest. In this study, we investigated the effect of different nitric oxide (NO) donors on the expression of the DNAM-1
ligand Poliovirus Receptor/CD155 (PVR/CD155) in multiple myeloma (MM) cells.
Methods: Six MM cell lines, SKO-007(J3), U266, OPM-2, RPMI-8226, ARK and LP1 were used to investigate the activity of
different nitric oxide donors [DETA-NO and the NO-releasing prodrugs NCX4040 (NO-aspirin) and JS-K] on the expression
of PVR/CD155, using Flow Cytometry and Real-Time PCR. Western-blot and specific inhibitors were employed
to investigate the role of soluble guanylyl cyclase/cGMP and activation of the DNA damage response (DDR).
Results: Our results indicate that increased levels of nitric oxide can upregulate PVR/CD155 cell surface and
mRNA expression in MM cells; in addition, exposure to nitric oxide donors renders myeloma cells more
efficient to activate NK cell degranulation and enhances their ability to trigger NK cell-mediated cytotoxicity.
We found that activation of the soluble guanylyl cyclase and increased cGMP concentrations by nitric oxide is
not involved in the up-regulation of ligand expression. On the contrary, treatment of MM cells with nitric oxide
donors correlated with the activation of a DNA damage response pathway and inhibition of the ATM /ATR/Chk1/2
kinase activities by specific inhibitors significantly abrogates up-regulation.
Conclusions: The present study provides evidence that regulation of the PVR/CD155 DNAM-1 ligand expression
by nitric oxide may represent an additional immune-mediated mechanism and supports the anti-myeloma activity
of nitric oxide donors.
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Multiple myeloma (MM) is a deadly hematologic cancer
characterized by latent accumulation of clonal secretory
plasma cells in the bone marrow. Despite advances in
therapeutic strategies, MM remains an incurable disease
with a median survival around 4–5 years in adults [1].
However, in the past decade, the use of autologous
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unless otherwise stated.introduction of new drugs, such as bortezomib and IMiDs,
have improved survival [2-5].
Increasing evidence in myeloma patients has shown
that Natural Killer (NK) cells can elicit potent allogeneic
and autologous responses to myeloma cells, strongly
supporting their anti-tumor potential in response to im-
munomodulatory drugs or following allogeneic stem cell
transplantation [6-8]. In this regard, several studies have
shown that triggering of different activating receptors,
such as DNAX accessory molecule-1 (DNAM-1), NK
group 2D (NKG2D) and Natural Cytotoxicity Receptors
(NCRs), is involved in the recognition and killing of MMThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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the DNAM1-ligands (DNAM1Ls) PVR/CD155 and Nectin-2
(Nec-2) [12] and the NKG2D-ligands (NKG2DLs) MICA/B
and ULBPs on the cell surface [9,12,13].
Nitric oxide (NO) is a reactive radical, highly diffusible
pleiotropic regulator of many different biological path-
ways, including vasodilatation, neurotransmission and
macrophage-mediated responses to infections. It is
generated from molecular oxygen and the amino acid
L-arginine through the action of the nitric oxide syn-
thase (NOS) enzymes; three isoforms of NOS have
been identified, a neuronal form (nNOS/NOS1) and
endothelial form (eNOS/NOS3) which are both consti-
tutively expressed enzymes producing physiological
levels of NO, and an inducible form (iNOS/NOS2)
which produces high levels of NO in a sustained man-
ner [14-16]. In the last years, the relationship between
NO and the pathology of malignant disorders has been
the subject of numerous studies; although the three
NOS isoforms are known to be present in most tumors
and generally expressed at higher levels compared to
their normal tissue counterparts, their functional role
still remains incompletely elucidated [17,18]. In this re-
gard, a concentration-dependent dual nature of NO has
been revealed, where low concentrations of NO can
promote invasion and metastases in different tumor
models or, on the contrary, high NO levels (e.g. immune
cell-generated NO) and the different reactive nitrogen
species (RNS) produced can inhibit tumor growth and
metastases (reviewed in [17,19,20]). Thus, NO may play
different roles in regulating cancer microenvironment
and progression, which can be cell-type and context
specific.
These observations suggest that tumor immune rejec-
tion through NO-dependent mechanism(s) can represent
an interesting promise for future tailored immunothera-
peutic anticancer strategies.
Our laboratory has recently shown that suboptimal
doses of different drugs, such as genotoxic chemothera-
peutics, inhibitors of the HSP-90 protein or of the GSK3
kinase, can increase the expression of several NK activat-
ing ligands on MM cells, via induction of specific regula-
tory transcriptional pathways [12,21,22]; the up-regulation
of these ligands on MM cells is associated with their
ability to trigger increased NK cell degranulation. At
this regard, expression of DNAM-1 ligands and in particu-
lar PVR/CD155 can be regulated by activation of a DNA
damage response (DDR) pathway induced by anticancer
drugs (e.g. doxorubicin or melphalan) or, in a different
context, by monocyte-derived reactive oxygen species
(ROS) in Ag-induced T cell proliferation [23].
Here, we analyzed the possibility that treatment of
MM cells with different NO-donors could regulate the
expression of the NK cell activating ligand PVR/CD155and, in turn, modify NK cell recognition and cytotoxicity
against these cancer cells.
Our results indicate that increased levels of NO can
enhance surface expression of PVR/CD155 on MM cell
lines, rendering these cells more susceptible to NK cell
mediated killing via DNAM-1 recognition. We found
that activation a DDR by NO is critical for these mech-
anisms since pharmacological inhibition of ATM/ATR
or Chk1/2 kinases as well as knockdown of E2F1, a
transcription factor activated in response to DNA damage,
significantly reduced NO-induced upregulation of PVR/
CD155.
Overall, our data demonstrate that NO can regulate
DNAM-1 ligand expression on MM cells, suggesting
novel roles of NO in immune response(s) to multiple
myeloma.
Methods
Cell lines
The human MM cell lines SKO-007(J3), U266, OPM-2,
ARK, RPMI-8226 and LP1 were kindly provided by Prof.
P. Trivedi (Sapienza University of Rome, Italy). SKO-007
(J3) cells transduced with a lentiviral vector expressing
shRNAs targeting E2F1 have been already described
[24]. The erythroleukemia cell line K562 and MM cell
lines were maintained at 37°C and 5% CO2 in RPMI
1640 (Life Technologies, Gaithersburg, MD) supplemented
with 10% FCS, 2 mM glutamine and 100 units/ml
penicillin-streptomycin (complete medium). All cell
lines were mycoplasma-free (EZ-PCR Mycoplasma
Test Kit, Biological Industries).
Reagents and antibodies
The nitric oxide donors DETA-NO [2,2′-(hydroxynitro-
sohydrazono) bis-ethanimine], NCX4040 (NO-aspirin),
JS-K [O2-(2,4-Dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-
1-yl]diazen-1-ium-1,2-diolate], caffeine, LY294002 and the
inhibitor of nitric oxide-sensitive guanylyl cyclase ODQ
(1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one) and Bafilo-
mycin A1, were purchased from Sigma-Aldrich (St. Louis,
MO). The Chk1/2 pharmacologic inhibitors SB218078
and UCN-01 were purchased from Calbiochem, EMD
Chemicals (Darmstadt, Germany). C12FDG was from
Invitrogen (Frederick, MD). The nitric oxide donor
DETA-NO (2 moles of NO• per mole of compound and a
half-life of 20 h at 37°C), is ideal for the treatment of cells
over long periods of time (e.g. 24–48 h). JS-K (an anti-
cancer agent belonging to the diazeniumdiolate family of
compounds), is designed to release nitric oxide (NO) in a
sustained and controlled manner within a cell, when me-
tabolized by glutathione S-transferases (GSTs).
The following monoclonal antibodies (mAbs) were used
for immunostaining or as blocking Abs: anti-PVR/CD155
(SKII.4) kindly provided by Prof. M. Colonna (Washington
Fionda et al. BMC Cancer  (2015) 15:17 Page 3 of 14University, St Louis, MO), anti-CD56 (C218) mAb was
provided by Dr. A. Moretta (University of Genoa, Genoa,
Italy), anti-DNAM-1 (DX11) from Serotec (Oxford, UK),
anti-Nec-2 (R2.525) from BD Biosciences (San Jose, CA),
anti-TIGIT (MBSA43) from eBioscience Inc. (San Diego,
CA). APC Goat anti-mouse IgG (Poly4053), anti-CD3/APC
(HIT3a), anti-CD56/PE (HCD56), mouse IgG1/FITC, /PE
or /APC isotype control (MOPC-21) were purchased from
BioLegend (San Diego, CA). Anti-CD107a/FITC (H4A3)
was purchased from BD Biosciences (San Jose, CA).
Immunofluorescence and flow cytometry
MM cell lines were cultured in 6-well tissue culture
plates for 48 h at a concentration of 2 × 105 cells/ml in
the presence of different concentrations of drugs. The
expression of PVR/CD155 on MM cells was analyzed by
immunofluorescence staining using an anti-PVR/CD155
unconjugated mAb, followed by secondary GAM-APC.
In all experiments, cells were stained with Propidium
Iodide (PI) (1 μg/ml) in order to assess cell viability
(always higher than 90% in the different treatments).
Nonspecific fluorescence was assessed by using an
isotype-matched irrelevant mAb (R&D System) followed
by the same secondary antibody. Fluorescence was ana-
lyzed using a FACSCalibur flow cytometer (BD Bioscience,
San Jose, CA) and FlowJo Flow Cytometric Data Analysis
Software (Tree Star, Inc. Ashland, OR).
Intracellular NO• levels were measured by flow cytom-
etry in cells loaded with the NO-sensitive dye DAF2-DA
[4,5-Diaminofluorescein-diacetate (Molecular Probes,
Invitrogen, San Diego, CA)]. Cells were gated by for-
ward/side scatter and fluorescence was recorded on the
FL-1 channel according to the manufacturer’s protocol.
Degranulation assay
NK cell-mediated cytotoxicity was evaluated using the
lysosomal marker CD107a as previously described [21].
As source of effector cells, we used primary NK cells ob-
tained from PBMCs isolated from healthy donors by
Lymphoprep (Nycomed, Oslo, Norway) gradient centri-
fugation and then co-cultured for 10 days with irradiated
(30 Gy) Epstein-Barr virus (EBV)-transformed B-cell line
RPMI 8866, without the addition of recombinant IL-2,
at 37°C in a humidified 5% CO2 atmosphere as previ-
ously described [25]. Informed consent in accordance
with the Declaration of Helsinki was obtained from all
donors, and approval was obtained from the Ethics
Committee of the Sapienza University of Rome, Italy.
On day 10, the cell population was routinely more than
90% CD56+CD16+CD3−, as assessed by immunofluores-
cence and flow cytometry analysis. Drug-treated MM
cells were washed twice in complete medium and then
incubated with NK cells at the effector:target (E:T) ratio
of 2.5:1, in a U-bottom 96-well tissue culture plate incomplete medium at 37°C and 5% CO2 for 2 h. There-
after, cells were washed with PBS and incubated with
anti-CD107a/FITC (or cIgG/FITC) for 45 min at 4°C.
Cells were then stained with anti-CD3/APC, anti-CD56/
PE to gate the CD3−CD56+ NK cell population. In some
experiments, cells were pre-treated for 20 min at room
temperature with anti-DNAM-1 or anti-TIGIT blocking
mAb. Fluorescence was analyzed using a FACSCalibur
flow cytometer (BD Bioscience, San Jose, CA) and
FlowJo Flow Cytometric Data Analysis Software (Tree
Star, Inc. Ashland, OR).
Cytotoxicity assay
A standard 4-hour chromium-release assay was used as
previously described [26]. SKO-007(J3) cells stimulated
as indicated above, were used as target cells and were
labeled (100–200 μCi 51Cr/106 cells; Amersham BioSciences,
Piscataway, NJ) for 90 minutes at 37°C, washed, and 5 × 103
cells/well were plated. As source of effector cells, we used
primary NK cells as described above. The percentage of
specific lysis was calculated by counting an aliquot of
supernatant and using the formula: 100 × [(sample re-
lease - spontaneous release)/total release - spontaneous
release)]. All determinations were made in triplicate, and
E:T ratios ranged from 10:1 to 1:1, as indicated.
Cell cycle analysis
SKO-007(J3) cell cycle distribution was analyzed by PI
staining after 48 h drug treatment. Cells were washed in
PBS with 0.1% sodium azide and fixed for 2 h at 4°C in
cold 70% ethanol. Thereafter, cells were incubated for
30 min at room temperature with 50 μg/mL of PI in
PBS containing 100 μg/mL of RNAse and immediately
analyzed using a FACSCalibur flow cytometer. Flow cy-
tometric analysis was performed using FlowJo software.
Analysis of senescent cells
Senescence Associated β-galactosidase assay was performed
using the fluorogenic substrate C12FDG to measure
β-galactosidase activity by flow cytometry. Cells were
incubated 1 h with 100 nM bafilomycin A1 to induce
lysosomal alkalinization, followed by 1 h incubation
with C12FDG (33 μM) and the C12-fluorescein signal
of senescent cells was measured on the FL-1 detector
using a FACSCalibur flow cytometer. Flow cytometric
analysis was performed using FlowJo software.
RNA isolation, RT-PCR and real-time PCR
Total RNA was extracted using TRIZOL™ (Life Technologies
Inc., Grand Island, NY), according to manufacturer’s instruc-
tions. The concentration and quality of the extracted
total RNA was determined by measuring light absorbance
at 260 nm (A260) and the ratio of A260/A280. Reverse
transcription was carried out in a 25 μl reaction volume
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protocol for M-MLV reverse transcriptase (Promega,
Madison, WI). Real-Time PCR was performed using the
ABI Prism 7900 Sequence Detection system (Applied
Biosystems, Foster City, CA). cDNAs were amplified in
triplicate with primers for CD155/PVR (Hs00197846_m1)
conjugated with fluorochrome FAM, and β-actin
(4326315E) conjugated with fluorochrome VIC (Applied
Biosystems). The level of ligand expression was measured
using Ct (threshold cycle). The Ct was obtained by sub-
tracting the Ct value of the gene of interest (PVR/CD155)
from the housekeeping gene (β-actin) Ct value. In the
present study we used Ct of the untreated sample as
the calibrator. The fold change was calculated accord-
ing to the formula 2-ΔΔCt, where ΔΔCt was the differ-
ence between Ct of the sample and the Ct of the
calibrator (according to the formula, the value of the
calibrator in each run is 1. The analysis was performed
using the SDS version 2.2 software (Applied Biosystems,
Foster City, CA).
Western-blot analysis
For Western-Blot analysis, SKO-007(J3) cells were pelleted,
washed once with cold phosphate-buffered saline, resus-
pended in lysis buffer [1% Nonidet P-40 (v/v), 10% gly-
cerol, 0.1% SDS, 0.5% Sodium Deoxycholate, 1 mM
phenyl-methyl-sulfonyl fluoride (PMSF), 10 mM NaF,
1 mM Na3VO4, COMPLETE protease1 inhibitor mix-
ture (Roche, Indianapolis, IN) in PBS] and subsequently
incubated 30 min on ice. The lysate was centrifuged at
14000 g for 15 min at 4°C and the supernatant was col-
lected as whole cell extract. Protein concentration was
determined by the BCA method (Pierce, Rockford, IL).
Thirty to 50 μg of cell extract were run on 10% denaturing
SDS-polyacrylamide gels. Proteins were then electroblotted
onto nitrocellulose membranes (Schleicher & Schuell,
Keene, NJ) and blocked in 3% milk in TBST buffer. Im-
munoreactive bands were visualized on the nitrocellu-
lose membranes, using horseradish-peroxidase-coupled
goat anti-rabbit or goat anti-mouse immunoglobulins
and the ECL detection system (GE Healthcare Amer-
sham), following the manufacturer’s instructions. Anti-
bodies against phospho-Chk1 (Ser317), phospho-Chk2
(Thr68), total Chk1 and total Chk2 were purchased
from Cell Signaling (Danvers, MA). Antibody against
phospho-H2A.X was purchased from Millipore (Billerica,
MA). Densitometric analysis was performed using Quantity
One software (Bio-Rad, Hercules, CA).
Results
Nitric oxide upregulates expression of DNAM-1 ligand
PVR/CD155 on human multiple myeloma cells
In order to characterize novel agents and molecular path-
ways able to regulate the expression of NK cell activatingligands in MM cells, we investigated the activity of nitric
oxide donors [DETA-NO and the NO-releasing pro-drugs
NCX4040 (NO-aspirin) and JS-K] on the expression of
the CD155/PVR, an activating DNAM-1 ligand regulated
by DDR and reactive radicals in different models [23,24].
We initially performed a flow cytometric analysis on
SKO-007(J3) MM cells after 48 h-treatment with DETA-
NO, a donor able to release 2 moles of NO• per mole of
compound and a half-life of 20 h at 37°C, ideal for the
treatment of cells over long periods of time (e.g. 24–48 h).
As shown in Figure 1A and B treatment of SKO-007(J3)
cells upregulated basal surface expression of PVR/CD155
ligand; the concentration of DETA-NO used in these ex-
periments (200 μM) has been chosen on the basis of
dose–response assays using minimal doses of the donor
[not affecting cell viability as assessed by PI staining (data
not shown)], able to increase intracellular levels of NO•
and to induce optimal PVR/CD155 expression (Additional
file 1A and D). At this regard, 200 μM is within a concen-
tration range of 0.1 to 1 mM DETA-NO, already shown to
be equivalent to about 200 to 400 nM NO concentrations
over a 24/48-hour period and comparable with reported
NO concentrations at different sites of active inflamma-
tion [27,28].
Previous observations have shown that this cell line
does not express detectable levels of the DNAM-1 ligand
Nec-2/CD112, as well as the other cell lines used in this
work (Additional file 2), and this ligand was not further
analyzed in this study [21]. We next examined whether a
possible mechanism underlying PVR/CD155 up-regulation
on MM cells could be the consequence of an increased
mRNA expression of this gene. Total RNA was isolated
from SKO-007(J3) cells exposed to DETA-NO for 24 h
and analyzed by Real-Time qRT-PCR. As shown in
Figure 1C, we found a significant increase of PVR/
CD155 mRNA levels in treated cells. We also investi-
gated the effect of DETA-NO on other MM cell lines
(U266, OPM-2, ARK, RPMI-8226 and LP-1) and confirmed
that PVR/CD155 was similarly upregulated in all cell lines
tested (Figure 1D-H). The concentration of DETA-NO
used for the different cell lines has been chosen on the
basis of dose–response assays using minimal doses of the
donor not affecting cell viability and able to induce opti-
mal PVR/CD155 expression (data not shown).
These results indicate that NO released by DETA-NO
can enhance cell surface expression and mRNA levels of
the DNAM-1 ligand PVR/CD155 in human MM cells.
Exposure to nitric oxide increases degranulation and NK
cell-mediated killing of MM cells
We tested whether treatment of myeloma cells with
DETA-NO could lead to increased activation and NK
cell-mediated killing. To this aim, we analyzed the de-
granulation activity of NK cells derived from healthy
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Figure 1 Regulation of PVR/CD155 expression on MM cell lines following treatment with NO donor DETA-NO. A) PVR/CD155 surface
expression was analyzed by flow cytometry on SKO-007(J3) cells treated with DETA-NO (200 μM) for 48 h. Data are representative of one out of
three independent experiments. The grey colored histogram represents basal expression, while thick black colored histogram represents the
expression after treatment with DETA-NO. B) The MFI of PVR/CD155 surface expression was calculated based on at least four independent
experiments and evaluated by paired Student t test (*P < 0.05). Histograms represent the MFI with specific mAb subtracted from the MFI value of
isotype control. These treatments did not affect the cell viability over the time and DETA-NO concentration [200 μM for SKO-007(J3)] chosen for
these experiments (as assessed by PI staining, data not shown). C) Real Time PCR analysis of total mRNA obtained from SKO-007(J3) cells, untreated (−)
or treated with 200 μM DETA-NO for 24 h as described above. Data, expressed as fold change units, were normalized with β-actin and referred
to the untreated cells considered as calibrator and represent the mean of 3 experiments (*P < 0.05). D-H) The MFI of PVR/CD155 surface expression
was calculated for U266, OPM-2, ARK, RPMI-8226 and LP1 MM cells, based on at least three independent experiments and evaluated by paired Student
t test (*P < 0.05). Histograms represent the MFI with specific mAb subtracted from the MFI value of isotype control. These treatments did not affect the
cell viability over the time and DETA-NO concentration [200 μM for U266, 50 μM for OPM-2, 200 μM for ARK, 100 μM for RPMI-8226 and 125 μM for
LP1] chosen for these experiments (as assessed by PI staining, data not shown).
Fionda et al. BMC Cancer  (2015) 15:17 Page 5 of 14donors against SKO-007(J3) cells, evaluating the expres-
sion of the CD107a (a surrogate marker for granule
mobilization) by FACS analysis. As shown in Figure 2A
and B, basal expression of CD107a on NK cells contact-
ing SKO-007(J3) was enhanced following treatment withDETA-NO. This increased degranulation was partially
dependent on DNAM-1 activation, because significantly
reduced in the presence of a blocking anti-DNAM-1
mAb. We also analyzed the possible role of the receptor
TIGIT (T cell Ig and ITIM domain), a coinhibitory
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Figure 2 NO exposed SKO-007(J3) cells enhances NK cell-mediated cytotoxicity. A) NK cells prepared from PBMCs of healthy donors, were
incubated with SKO-007(J3) cells, untreated or treated with DETA-NO for 48 h, and used as target cells in a degranulation assay. The assay was
performed at the effector:target (E:T) ratio of 2.5:1. After 2 hours at 37°C, cells were stained with anti-CD56, anti-CD3 and anti-CD107a mAbs. Cell
surface expression of CD107a was analyzed on CD56+CD3− cells. In order to evaluate the role of DNAM-1, the assay was performed in parallel
treating NK cells with blocking anti-DNAM-1 antibody. Results are representative of one out of three independent experiments. B) The MFI of
CD107 were calculated based on at least three independent experiments and evaluated by paired Student t test (*P < 0.05). Histograms represent
the MFI with specific mAb subtracted from the MFI value of isotype control. C) NK cells isolated from PBMCs of healthy donors were incubated
with SKO-007(J3) cells, untreated or treated with DETA-NO for 48 h as described above, and used as target cells in a standard 4-hour chromium-release
assay. The percentage of specific lysis was calculated by counting an aliquot of supernatant and using the formula: 100 x [(sample release -
spontaneous release)/total release - spontaneous release)]. All determinations were made in triplicate and E:T ratios ranged from 10:1 to 1:1,
as indicated. Data represent the mean (n = 3 experiments, *P < 0.05).
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gands, expressed in NK cells as well as in different T cell
subsets [29,30]; as shown in Additional file 3, the pres-
ence of a blocking anti-TIGIT mAb did not significantly
modify basal or the increased degranulation induced by
DETA-NO, suggesting that triggering of this receptor is
not able to modulate the activity of NK cells, at least in
this experimental setting. As a control for a possible dir-
ect effect of NO on NK cell functions, we also analyzed
the degranulation activity of NK cells contacting SKO-
007(J3) cells in the presence of DETA-NO; as shown in
Additional file 4, degranulation activity was not signifi-
cantly affected by the presence of the donor.
Finally, we analyzed the effect of DETA-NO on NK
cell cytolytic function; as shown in Figure 2C, standardcytotoxicity assays using 51Cr-labeled SKO-007(J3) target
cells were performed, and treatment with DETA-NO sig-
nificantly increased specific killing when compared to
the cytotoxicity of untreated cells.
Our results, therefore, indicate that increased ex-
pression of PVR/CD155 in SKO-007(J3) cells treated
with DETA-NO enhances NK cell degranulation and
killing by promoting DNAM-1 recognition.
Molecular mechanisms involved in PVR/CD155
up-regulation by NO
One of the most studied mechanisms involved in physio-
logical pathways regulated by NO is the activation of the
heme iron in the soluble guanylate cyclase (sGC), able to
stimulate cGMP production and activation of downstream
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pathway might be involved in PVR/CD155 up-regulation
in MM cells, SKO-007(J3) cells were treated with DETA-
NO in the presence or absence of ODQ, a widely used
specific inhibitor of soluble guanylate cyclase used to
differentiate cGMP-mediated effects of NO from cGMP-
independent effects [33,34]. However, as shown in
Figure 3A, up-regulation of PVR/CD155 was not affected
by ODQ, suggesting that cGMP-mediated signalling was
not involved.
Nitric oxide can also interact directly with biological
target molecules, nonetheless, when generated in high
amounts such as during inflammation, it can exert indir-
ect effects, reacting with superoxide anion to produce dif-
ferent reactive nitrogen species (RNS) [e.g. peroxynitrite
(a strong oxidant)] with significant pathophysiological/in-
flammatory actions (reviewed in [35,36]). In this regard,
the different actions of NO in tumor biology may be in
part explained by the complex dose-dependent interac-
tions of NO and the related RNS with DNA, producing
both single and double-strand breaks and genotoxic stressA
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Figure 3 NO enhances PVR/CD155 expression: molecular mechanisms
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Data shown are representative of 1 out of 2 independent experiments.[20,37]. As our laboratory has recently shown that geno-
toxic drugs (e.g. melphalan or doxorubicin) can trigger
the expression of NK activating ligands on MM cells in
an ATM/ATR/Chk1/2-dependent and p53-independent
manner [12,24], we investigated the possibility that a
similar mechanism might be involved in the presence of
NO donors. We analyzed the activation of ATM/ATR-
dependent down-stream signalling components, such as
H2A.X and Chk1/2 kinases, already described to phos-
phorylate and activate effector proteins that inhibit cell
cycle progression and to activate DNA repair [38,39]; as
shown in Figure 3B and C, DETA-NO was able to induce
H2A.X phosphorylation on residue Ser139 (pH2A.X) and
Chk1 and Chk2 phosphorylation on Ser317 and Thr68, re-
spectively. In this regard, as shown in Figure 4A and B
(and Additional file 5A,B), up-regulation of PVR/CD155
expression was significantly inhibited by caffeine or by
LY294002 in SKO-007(J3) cells, two widely used inhibi-
tors capable of blocking both ATM and ATR catalytic
activity [40], and by SB218078 or UCN-01, inhibitors of
Chk1/2 kinases (Figure 4C,D and Additional file 5C,D).stim.
TA-NO
TA-NO + ODQ  
C
. A) PVR/CD155 surface expression was analyzed by flow cytometry on
ce of the guanylate cyclase inhibitor ODQ (50 μM) for 48 h. Data are
lot analysis of total cellular proteins from SKO-007(J3) cells treated with
-actin, used as loading control. The proteins transferred to nitrocellulose
ein had been loaded in each lane. Data shown are representative of 1
oteins from SKO-007(J3) cells treated with DETA-NO for 18 h. Lysates were
k2, wt Chk1 and Chk2 or β-actin, used as loading control. The proteins
rify that similar amounts of protein had been loaded in each lane.
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Figure 4 NO enhances PVR/CD155 expression: role of DDR. A,B) PVR/CD155 surface expression was analyzed by flow cytometry on SKO-007
(J3) cells treated with DETA-NO (200 μM) in the presence or absence of caffeine (CAF 1 mM) or LY294002 (LY 20 μM) for 48 h. Data are representative
of one out of four independent experiments. C,D) PVR/CD155 surface expression was analyzed by flow cytometry on SKO-007(J3) cells treated
with DETA-NO (200 μM) in the presence or absence of the Chk1/2 inhibitors SB218078 and UCN-01 (0.5 μM and 50 nM respectively) for 48 h.
Data are representative of one out of four independent experiments. In these experiments, the concentration used for the different inhibitors,
did not significantly affect cell viability as assessed by PI staining (data not shown). E) Real Time PCR analysis of total mRNA obtained from
SKO-007(J3) cells, treated for 24 h in the presence or absence of caffeine (1 mM) as described above. Data, expressed as fold change units, were
normalized with β-actin and referred to the untreated cells considered as calibrator and represent the mean of 3 experiments (*P < 0.05). F) PVR/CD155
surface expression was analyzed by flow cytometry on SKO-007(J3) non-target shRNA (shRNA-control) or pLKO-sh-E2F1 cells, treated with DETA-NO as
described above. Data are representative of one out of three independent experiments. G) The MFI of PVR/CD155 surface expression was calculated
based on at least three independent experiments and evaluated by paired Student t test (*P < 0.05). Histograms represent the MFI with specific mAb
subtracted from the MFI value of isotype control.
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PVR/CD155 mRNA levels in DETA-NO + caffeine-
treated cells (Figure 4E) and, in addition, up-regulation
of PVR/CD155 expression was significantly inhibitedin SKO-007(J3) cells in which the expression of E2F1
was reduced by shRNA interference (already described
in [24]), a transcription factor activated/stabilized by
ATM/ATR and Chk2 [41-43] and recently shown to
Fionda et al. BMC Cancer  (2015) 15:17 Page 9 of 14upregulate the expression of PVR/CD155 in MM cells
exposed to genotoxic drugs [24]. These results indicate
that NO-mediated activation of DDR is involved in the
up-regulation of PVR/CD155 in MM cells.
NO/DDR-induced up-regulation of PVR/CD155 is not
related to a senescence-dependent mechanism
We have previously demonstrated that genotoxic drugs
(e.g. doxorubicin)-induced up-regulation of PVR/CD155
is associated with a senescence-dependent G2/M cell
cycle arrest in MM cells [12]. Here, we investigated the
possible link between DDR, cell cycle, induction of sen-
escence and the ability of NO to induce PVR/CD155
expression. As shown in Figure 5A, stimulation of SKO-
007(J3) cells with DETA-NO or with doxorubicin in-
creased basal cell surface expression of PVR/CD155;
however, only doxorubicin could activate a senescence-
dependent G2/M cell cycle arrest (Figure 5B and C) asBA
Unsimulated DETA-
G1 = 62.5
S   = 20.5
G2 = 15.6
G1 
S   
G2 
C
PVR/CD155
DETA-NO
IgG
DOXO
IgG
Figure 5 NO-induced up-regulation of PVR/CD155 is not related to a
expression was analyzed by flow cytometry on SKO-007(J3) cells treated wi
representative of one out of three independent experiments. The grey colo
while thick black colored histograms represent the expression after treatme
treated with DETA-NO or with doxorubicin for 48 h as described above. Da
The grey colored histograms represent the C12-fluorescein signal. C) SKO-0
described above. Cells were fixed and stained with PI to analyze cell distribindicated by the different levels of SA-βGal activity and
G2/M quantification. These data suggest that different
(DDR)-related pathways may be triggered by these drugs
and that cellular senescence is not correlated or involved
in NO-induced up-regulation of PVR/CD155 in MM
cells.
Anticancer nitric oxide-releasing prodrugs upregulates
expression of PVR/CD155 on human multiple
myeloma cells
Rational design of pharmacological agents (including
NO-donors) takes account of specific modifications of
known molecules with the purpose of optimizing their
properties mainly in terms of efficacy and safety. In this
context, the use of compounds that generate NO spontan-
eously for the treatment of malignancies is precluded due
to the potential general toxic effects of NO. Thus, we in-
vestigated also the activity of novel prototype anticancerUnstimulated
DETA-NO
Doxorubicin
NO Doxorubicin
= 42.66
= 44.29
= 13.04
G1 = 10.42
S   = 21.24
G2 = 59.78
C12FDG fluorescence
senescence-dependent mechanism. A) PVR/CD155 surface
th DETA-NO (200 μM) or with doxorubicin (0.05 μM) for 48 h. Data are
red histograms represent basal expression of the indicated ligand,
nt with the indicated drug. B) SA-βGal activity of SKO-007(J3) cells
ta are representative of one out of three independent experiments.
07(J3) cells were treated for 48 hours with the indicated drug as
ution among the different cell-cycle phases.
Fionda et al. BMC Cancer  (2015) 15:17 Page 10 of 14NO-releasing prodrugs on the expression of PVR/CD155.
To this aim, we treated SKO-007(J3) cells with the NO-
releasing aspirin derivative NCX4040 (a bio-activated ni-
tric oxide-donating non-steroidal anti-inflammatory drug)
[44] or with JS-K, an anti-cancer agent designed to release
nitric oxide in a sustained manner within a cell when me-
tabolized by glutathione S-transferases (GSTs), enzymes
frequently overexpressed in different tumors, including
MM [45,46]. The concentration of donors used in
these experiments have been chosen on the basis of
dose–response assays using minimal doses of the specific
donor (not affecting cell viability as assessed by PI stain-
ing, data not shown), able to induce optimal PVR/CD155
expression (Additional file 1B and C).
As shown in Figure 6, treatment of SKO-007(J3) cells
with NCX4040 or with JS-K at micromolar concentrations
(known to generate significant levels of intracellular NO
in different cell lines, including MM [44-46]), upregulated
the basal cell surface expression of PVR/CD155, confirm-
ing the data obtained using DETA-NO and suggesting the
use of novel NO-releasing prodrugs as an additional classA
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Figure 6 Regulation of PVR/CD155 expression on MM cell lines follow
JS-K. A) PVR/CD155 surface expression was analyzed by flow cytometry on
representative of one out of three independent experiments. The grey colo
while thick black colored histogram represents the expression after treatme
calculated based on at least three independent experiments and evaluated
specific mAb subtracted from the MFI value of isotype control. C) Molecula
by flow cytometry on SKO-007(J3) cells treated with JS-K (3 μM) for 48 h. D
The grey colored histogram represents basal expression of the indicated lig
after treatment with JS-K. E) The MFI of PVR/CD155 surface expression was
evaluated by paired Student t test (*P < 0.05). Histogram represents the MF
F) Molecular structure of JS-K. The concentration of the indicated donor us
assessed by PI staining (data not shown).of regulators of the expression of DNAM-1 ligand in can-
cer cells.
Discussion and conclusion
Anticancer immune responses may contribute to the con-
trol of tumors after conventional chemotherapy and dif-
ferent observations have indicated that chemotherapeutic
agents (e.g. genotoxic drugs) or adjuvant radiotherapy can
induce immune responses that result in immunogenic
cancer cell death or immunostimulatory side effects
[47-50]. In this regard, increasing experimental and
clinical evidence highlight the importance of NK cells in
immune responses toward MM and combination ther-
apies able to enhance the activity of NK cells against
MM are showing promise in treating this hematologic
cancer. Recently, a novel connection between thera-
peutic immuno-modulation and chemotherapy has been
the finding that anti-cancer drugs (e.g. genotoxic agents,
inhibitors of histone deacetylases, of the proteasome or of
the HSP-90 chaperone) can increase the expression of
DNAM-1 and NKG2D activating ligands, thus enhancingNCX4040 
NitroAspirin
Untreated
NCX4040
JS-K
D155
Untreated
JS-K
CD155
*
C
F
ing treatment with the NO-releasing prodrugs NitroAspirin and
SKO-007(J3) cells treated with NCX4040 (10 μM) for 48 h. Data are
red histogram represents basal expression of the indicated ligand,
nt with NCX4040. B) The MFI of PVR/CD155 surface expression was
by paired Student t test (*P < 0.05). Histograms represent the MFI with
r structure of NCX4040. D) PVR/CD155 surface expression was analyzed
ata are representative of one out of three independent experiments.
and, while thick black colored histogram represents the expression
calculated based on at least three independent experiments and
I with specific mAb subtracted from the MFI value of isotype control.
ed in these experiments, did not significantly affect cell viability as
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cells, NKT cells and CTLs) against tumor cells, including
MM [11,12,21,24,51-54].
Different and contradictory results have been reported
about the role of nitric oxide in cancer progression, me-
tastases and treatment of disease (reviewed in [19,20]).
Initial findings suggested that immune cell-generated
NO can be cytostatic or cytotoxic for a number of tu-
mors; indeed, several reports have shown that macro-
phages can selectively destroy different tumor types
(in vitro and in vivo) through the production of high
levels of NO [55-58]. Moreover, NO can also enhance
the cytotoxicity of NK cells and regulate survival of den-
dritic cells [59-61] and its release in models of lung and
hepatic metastases microvasculature has been associ-
ated to a natural local defense mechanism inducing
tumor cell killing [62,63]. On the other hand, other find-
ings highlighted opposite actions mediated by NO, lead-
ing to increased tumor growth; in this context, low
concentrations of NO have been shown to promote in-
vasion and metastases (reviewed in [17,20]) and produc-
tion of NO within specific tumor microenvironments
has been described to enhance tumor progression,
mainly by stimulating angiogenesis and/or to repress T
cell responses by CD11b+/Gr-1+ myeloid cells (reviewed
in [17]).
The observations described in this work can provide
additional information on the role of nitric oxide in can-
cer and in MM. In particular, we investigated the effect
of nitric oxide on the expression of the DNAM-1 ligand
PVR/CD155 in MM cells. We found that treatment of
MM cell lines with nitric oxide donors (DETA-NO,
NitroAspirin/NCX4040 or JS-K) can increase the expres-
sion of this ligand, rendering these cells more susceptible
to NK cell-mediated killing (Figure 2). Moreover, we iden-
tified one of the possible mechanism(s) involved in this
up-regulation, the activation of a DNA damage response,
a molecular pathway already described to regulate the ex-
pression of NK cells activating ligands in several cellular
models [12,24,64]. NO-generated nitrogen species [20,37]
and the consequent production of single and/or double
DNA strand breaks can activate DDR in MM cells (as
shown in Figure 3B and C); in this regard, upregulation of
PVR/CD155 by DETA-NO was significantly reduced by
inhibitors of ATM/ATR catalytic activity (caffeine and
LY294002) and by inhibitors of the Chk1/2 kinases
(SB218078 and UCN-01) (Figure 4C-D). In addition, silen-
cing of E2F1, a transcription factor activated/stabilized by
ATM/ATR/Chk2 [41-43] and described to upregulate the
expression of PVR/CD155 in MM cells exposed to geno-
toxic drugs [24], resulted in a marked reduction of PVR/
CD155 up-regulation (Figure 4E and F). These results in-
dicate that NO-mediated activation of DDR is involved in
the up-regulation of PVR/CD155 and that one of themechanism(s) underlying this regulation implicates the ac-
tivity of E2F1. Interestingly, and differently from our pre-
vious observation that up-regulation of PVR/CD155 is
preferentially associated with a senescence-dependent G2/
M cell cycle arrest [12], NO failed to activate a senescence
and G2/M cell cycle arrest in our experimental system, as
indicated by the different levels of SA-βGal activity and
G2/M phase between DETA-NO and doxorubicin-treated
cells (used here as positive control) (Figure 5B and C).
These data suggest that specific molecular pathways acti-
vated by RNSs and/or a different strength of DDR might
be induced by these drugs and that cellular senescence is
not correlated or involved in up-regulation of PVR/
CD155. Moreover, the three NO-donors used in this work
differ in their capability to upregulate PVR/CD155 expres-
sion, at least in our experimental setting of donor concen-
tration and duration of treatment (as shown in Figures 1
and 6); these differences might reflect the possibility that
additional molecular action(s) besides NO release might
contribute to donors biologic activities, in particular medi-
ated by the aspirin-moiety (NCX4040) or by the JS-K’s
arylating ability on different nucleophilic biomolecules
[65]. Further experiments will be needed to better
characterize possible differences in activation of DDR
by these drugs and the correlation with the expression
of activating ligands.
Work by other groups has demonstrated a direct
cytotoxic/anti-myeloma activity of NO as a consequence
of induction of DDR, using the NO-releasing prodrug JS-
K [46], which can also affect the interaction of MM cells
with bone marrow microenvironment, modulating tumor
angiogenesis in vivo and in vitro [66]. Moreover, NO can
function as a negative feedback signal to limit pathologic
osteoclastogenesis via RANKL/iNOS/NO autoregulatory
pathway [67]. In a different context, treatment with JS-K
or the activation of macrophage-dependent NO expres-
sion after IL-2 + anti-CD40 immunotherapy has been
shown to modulate metastatic progression in an orthoto-
pic model of renal cell carcinoma [68]. Similarly, local pro-
duction of significant amounts of NO by iNOS+ has been
also shown to deeply affect the activity of pro-tumoral mi-
croenvironments, as demonstrated using neoadjuvant
local low-doses of gamma irradiation (LDI) in a model of
pancreatic carcinogenesis [69]; in this model, LDI is able
to redirect local (or pre-adoptive-transfer) macrophage
differentiation from a cancer-promoting immunosuppres-
sive state to an iNOS+ phenotype, to normalize aberrant
angiogenesis-driven vascular abnormalities and to en-
able infiltration of cytotoxic T cells. In this regard, local
MM-associated macrophages play a crucial role in the
pathophysiology of MM and can promote plasma cell
growth with aberrant vasculogenesis (reviewed in [70]);
moreover, hypoxia-mediated impairment of NO signal-
ling can also contribute to tumor escape from NK cell
Fionda et al. BMC Cancer  (2015) 15:17 Page 12 of 14immunesurveillance by inducing shedding of the NKG2DL
MICA, through a mechanism involving increased expres-
sion/activity of ADAM10 via HIF-1α [71,72].
The possibility to regulate activating ligands such as
PVR/CD155 in MM cells, able to enhance the activity of
cytotoxic lymphocytes (e.g. NK cells) by pharmacological
delivery of NO-releasing prodrugs (also in combined
immunotherapy) or local production of NO by “therapy-
reprogrammed” or adoptively transferred iNOS+ macro-
phages, might be considered as an additional strategy to hit
the tumor and to modify local microenvironment allowing
and/or enhancing immuno-therapeutic applications.
Additional files
Additional file 1: A-C) Dose–response assays using minimal doses
of the indicated donor (not affecting cell viability as assessed by PI
staining, data not shown) able to induce optimal PVR/CD155
expression in SKO-007(J3) cells after 48 h treatment. The optimal
doses chosen (indicated in bold) were: DETA-NO 200 μM, NCX4040 10
μM, JS-K 3 μM. D) Intracellular NO• levels in SKO-007(J3) cells after 24 h
treatment with DETA-NO 200 μM.
Additional file 2: Nec-2/CD112 surface expression was analyzed by
flow cytometry on SKO-007(J3), U266, OPM-2, ARK, RPMI-8226 and
LP1 MM cells. K562 cells were used here as positive control. The thin
black colored histogram represents IgG-control while grey colored
histogram represents the expression of Nec-2.
Additional file 3: NK cells prepared from PBMCs of healthy donors
were incubated with SKO-007(J3) cells, untreated or treated with
DETA-NO for 48 h, and used as target cells in a degranulation assay.
The assay was performed at the effector:target (E:T) ratio of 2.5:1. After 2
hours at 37°C, cells were stained with anti-CD56, anti-CD3 and anti-CD107a
mAbs. Cell surface expression of CD107a was analyzed on CD56+CD3− cells.
In order to evaluate the role of TIGIT, the assay was performed in parallel
treating NK cells with blocking anti-TIGIT antibody. Results are representative
of one out of two independent experiments.
Additional file 4: NK cells prepared from PBMCs of healthy donors
were incubated with SKO-007(J3) cells as described above, and used
as target cells in a degranulation assay. The assay was performed at
the effector:target (E:T) ratio of 2.5:1, in the presence or in the absence of
DETA-NO 200 μM. After 2 hours at 37°C, cells were stained with anti-CD56,
anti-CD3 and anti-CD107a mAbs. Cell surface expression of CD107a was
analyzed on CD56+CD3− cells. Results are representative of one out of
two independent experiments.
Additional file 5: A,B) PVR/CD155 surface expression was analyzed
by flow cytometry on SKO-007(J3) cells treated with DETA-NO
(200 μM) in the presence or absence of caffeine (CAF 1 mM) or
LY294002 (LY 20 μM) for 48 h. C,D) PVR/CD155 surface expression was
analyzed by flow cytometry on SKO-007(J3) cells treated with DETA-NO
(200 μM) in the presence or absence of the Chk1/2 inhibitors SB218078
and UCN-01 (0.5 μM and 50 nM respectively) for 48 h. The MFI of PVD/CD155
expression was calculated based on at least four independent experiments
and evaluated by paired Student t test (*P < 0.05). Histograms represent the
MFI with specific mAb subtracted from the MFI value of isotype control.
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